An evaluation of the exposure-efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn's disease: Pharmacokinetic findings from VISIBLE 2

被引：0
|
作者：
Chen, C. [1 ]
Rosario, M. [4 ]
Polhamus, D. [5 ]
Zhang, W. [2 ]
Kisfalvi, K. [3 ]
Feagan, B. [7 ]
Sandborn, W. [6 ,8 ]
Vermeire, S.
D'Haens, G. [9 ]
机构：
[1] Takeda, Quantitat Clin Pharmacol, Global Clin Sci, Cambridge, MA USA
[2] Takeda, Res & Dev, Stat & Quantitat Sci, Cambridge, MA USA
[3] Takeda, Res & Dev, Global Clin Sci, Cambridge, MA USA
[4] Takeda, Clin Pharmacol, Deerfield, IL USA
[5] Metrum Res Grp, Tariffville, CT USA
[6] Univ Calif San Diego, Div Gastroenterol, San Diego, CA 92103 USA
[7] Western Univ, Robarts Clin Trials, London, ON, Canada
[8] Univ Hosp Leuven, Dept Gastroenterol, Leuven, Belgium
[9] Amsterdam Univ Med Ctr, Dept Gastroenterol, Amsterdam, Netherlands
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2020年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
133
引用
收藏
页码：117 / 118
页数：2
相关论文
共 50 条
  • [1] An evaluation of the exposure-efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn's disease: Pharmacokinetic findings from VISIBLE 2
    Chen, C.
    Rosario, M.
    Polhamus, D.
    Dirks, N.
    Zhang, W.
    Sun, W.
    Kisfalvi, K.
    Feagan, B.
    Sandborn, W.
    Vermeire, S.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S056 - S057
  • [2] AN EVALUATION OF THE EXPOSURE-EFFICACY RELATIONSHIP FOR SUBCUTANEOUS VEDOLIZUMAB MAINTENANCE TREATMENT OF CROHN'S DISEASE: PHARMACOKINETIC FINDINGS FROM VISIBLE 2
    Chen, Chunlin
    Rosario, Maria
    Polhamus, Daniel
    Dirks, Nathanael L.
    Zhang, Wenwen
    Sun, Wan
    Kisfalvi, Krisztina
    Feagan, Brian G.
    Sandborn, William J.
    Vermeire, Severine
    D'Haens, Geert R.
    GASTROENTEROLOGY, 2020, 158 (06) : S458 - S458
  • [3] Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis
    D'Haens, Geert
    Rosario, Maria
    Polhamus, Daniel
    Dirks, Nathanael L.
    Chen, Chunlin
    Kisfalvi, Krisztina
    Agboton, Christian
    Vermeire, Severine
    Feagan, Brian G.
    Sandborn, William J.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2024, 17 (04) : 403 - 412
  • [4] Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease
    Rosario, Maria
    French, Jonathan L.
    Dirks, Nathanael L.
    Sankoh, Serap
    Parikh, Asit
    Yang, Huyuan
    Danese, Silvio
    Colombel, Jean-Frederic
    Smyth, Michael
    Sandborn, William J.
    Feagan, Brian G.
    Reinisch, Walter
    Sands, Bruce E.
    Sans, Miguel
    Fox, Irving
    JOURNAL OF CROHNS & COLITIS, 2017, 11 (08): : 921 - 929
  • [5] Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial
    Vermeire, Severine
    D'Haens, Geert
    Baert, Filip
    Danese, Silvio
    Kobayashi, Taku
    Loftus, Edward, V
    Bhatia, Siddharth
    Agboton, Christian
    Rosario, Maria
    Chen, Chunlin
    Zhang, Wenwen
    Kisfalvi, Krisztina
    Sandborn, William J.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 (01): : 27 - 38
  • [6] Efficacy and safety of vedolizumab subcutaneous formulation in patients with moderately to severely active Crohn's disease: Results of the VISIBLE 2 study
    Vermeire, S.
    Sandborn, W.
    Danese, S.
    Baert, F.
    Kobayashi, T.
    Loftus, E.
    Bhatia, S.
    Kisfalvi, K.
    Rosario, M.
    Zhang, W.
    D'Haens, G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 115 - 115
  • [7] Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease (vol 11, pg 921, 2017)
    Rosario, Maria
    French, Jonathan L.
    Dirks, Nathanael L.
    Sankoh, Serap
    Parikh, Asit
    Yang, Huyuan
    Danese, Silvio
    Colombel, Jean-Frederic
    Smyth, Michael
    Sandborn, William J.
    Feagan, Brian G.
    Reinisch, Walter
    Sands, Bruce E.
    Sans, Miguel
    Fox, Irving
    JOURNAL OF CROHNS & COLITIS, 2018, 12 (04): : 510 - 510
  • [8] Exposure-response relationship of vedolizumab subcutaneous treatment in patients with ulcerative colitis: VISIBLE 1
    Rosario, M.
    Polhamus, D.
    Dirks, N.
    Lock, R.
    Yao, X.
    Chen, J.
    Chen, C.
    Sun, W.
    Feagan, B.
    Sandborn, W.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S377 - S378
  • [9] Exposure-response relationship of vedolizumab after 6 weeks of treatment in adults with Crohn's disease
    Rosario, M.
    French, J.
    Dirks, N.
    Milton, A.
    Fox, I.
    Gastonguay, M.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S270 - S270
  • [10] NETWORK META-ANALYSIS TO EVALUATE THE COMPARATIVE EFFICACY OF INTRAVENOUS AND SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS
    Peyrin-Biroulet, Laurent
    Bossuyt, Peter
    Bettenworth, Dominik
    Loftus, Edward V.
    Anjie, Suzanne I.
    D'Haens, Geert
    Saruta, Masayuki
    Perttu, Arkkila
    Kim, Dong-Hyeon
    Choi, Dasom
    Reinisch, Walter
    GASTROENTEROLOGY, 2023, 164 (06) : S654 - S654
12345